Latest news

• NICE set to back Parsabiv for kidney disease complication

  be treated with Amgen's older drug Sensipar/Mimpara (cinacalcet) - and provided Amgen supplies the drug at an agreed discount. ... Specifically, it is administered three times a week as an infusion at the end of the dialysis process, while cinacalcet

• Amgen's chronic kidney disease drug Parsabiv cleared in US

  Parsabiv (etelcalcetide) - a follow-up to Amgen's blockbuster Sensipar/Mimpara (cinacalcet) - has been given a green light to treat adult CKD patients on dialysis who develop secondary hyperparathyroidism (sHPT).

• FDA knocks back Amgen's chronic kidney disease treatment

  The rejection is a big disappointment for Amgen, which had suggested that Parsabiv (also known as velcalcetide and AMG 416) could equal and potentially exceed Sensipar (cinacalcet) as a revenue driver.

• Amgen's Sensipar follow-up clears phase III trial

  Now, Amgen is edging close to bringing a successor to Sensipar (cinacalcet) to market after follow-up AMG 416 (formerly known as velcalcetide) met its objectives in a phase III trial

• Amgen profits down on rising costs

  Among Amgen's other new products, Sensipar/Mimpara (cinacalcet) for hyperparathyroidism grew 19 per cent to $256m, while Xgeva and Prolia (both denosumab) for preventing bone fractures rose 72 per cent